Laboratory services provider Labcorp has launched the new blood-based test, ATN Profile, for the diagnosis of Alzheimer’s disease.
The test combines three blood biomarkers, known as amyloid plaques, tau tangles and neurodegeneration (ATN), for detecting and evaluating biological changes associated with the disease.
Patients undergoing evaluation for Alzheimer’s disease or other causes of cognitive impairment based on clinical observation and cognitive screenings can access the test through their physicians.
The interpretable test will help physicians evaluate pathologies associated with Alzheimer’s and other neurodegenerative conditions in suitable patients.
Healthcare providers have the option to order the ATN Profile, comprising blood Aß42/40, pTau 181 and NfL, or they can opt for individual tests.
Labcorp chief medical and scientific officer Dr Brian Caveney said: “Many patients experience uncertainty around Alzheimer’s disease risk, which can take months or even years to diagnose.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
“More definitive testing, including our new ATN profile, can provide objective insights to patients, their loved ones and treating physicians as they navigate care and treatment.”
The US Centers for Disease Control and Prevention (CDC) reports that approximately 6.7 million Americans currently have Alzheimer’s disease and this number is projected to almost triple to reach 14 million by 2060.
In June this year, Labcorp launched a new liquid biopsy test known as Labcorp Plasma Focus which enables the detection of targeted therapies and improved care for patients with advanced or metastatic solid tumours.
The test will allow oncologists to evaluate circulating cell-free DNA (cfDNA) released by tumour cells and offer personalised, targeted therapy plans for patients.